Vis enkel innførsel

dc.contributor.authorSofias, Alexandros Marios
dc.contributor.authorToner, Yohana C.
dc.contributor.authorMeerwaldt, Anu E.
dc.contributor.authorvan Leent, Mandy M. T.
dc.contributor.authorSoultanidis, Georgios
dc.contributor.authorElschot, Mattijs
dc.contributor.authorGonai, Haruki
dc.contributor.authorGrendstad, Kristin
dc.contributor.authorFlobak, Åsmund
dc.contributor.authorNeckmann, Ulrike
dc.contributor.authorWolowczyk, Camilla
dc.contributor.authorFisher, Elizabeth L.
dc.contributor.authorReiner, Thomas
dc.contributor.authorDavies, Catharina de Lange
dc.contributor.authorBjørkøy, Geir
dc.contributor.authorTeunissen, Abraham J. P.
dc.contributor.authorOchando, Jordi
dc.contributor.authorPérez-Medina, Carlos
dc.contributor.authorMulder, Willem J. M.
dc.contributor.authorHak, Sjoerd
dc.identifier.citationACS Nano. 2020, 14 (7), 7832-7846.en_US
dc.description.abstractAlthough the first nanomedicine was clinically approved more than two decades ago, nanoparticles’ (NP) in vivo behavior is complex and the immune system’s role in their application remains elusive. At present, only passive-targeting nanoformulations have been clinically approved, while more complicated active-targeting strategies typically fail to advance from the early clinical phase stage. This absence of clinical translation is, among others, due to the very limited understanding for in vivo targeting mechanisms. Dynamic in vivo phenomena such as NPs’ real-time targeting kinetics and phagocytes’ contribution to active NP targeting remain largely unexplored. To better understand in vivo targeting, monitoring NP accumulation and distribution at complementary levels of spatial and temporal resolution is imperative. Here, we integrate in vivo positron emission tomography/computed tomography imaging with intravital microscopy and flow cytometric analyses to study αvβ3-integrin-targeted cyclic arginine-glycine-aspartate decorated liposomes and oil-in-water nanoemulsions in tumor mouse models. We observed that ligand-mediated accumulation in cancerous lesions is multifaceted and identified “NP hitchhiking” with phagocytes to contribute considerably to this intricate process. We anticipate that this understanding can facilitate rational improvement of nanomedicine applications and that immune cell–NP interactions can be harnessed to develop clinically viable nanomedicine-based immunotherapies.en_US
dc.publisherACS - American Chemical Societyen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleTumor Targeting by αvβ3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhikingen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.source.journalACS Nanoen_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal